Partnering Key To Bayer’s Eylea Good Start In Japan
This article was originally published in The Pink Sheet Daily
Bayer's three new products – Eylea, Xarelto and Stivarga – are off to a good start in the marketplace, says interim pharma head Wolfgang Plischke. Eylea has 48% Japanese market share for wet AMD.
You may also be interested in...
Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.